Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: The Borealis-Atrial Fibrillation Study

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 6, 2014, Pages 824-830

  Buller, H R ^a   Halperin, J ^b   Hankey, G J ^c,d   Pillion, G ^e   Prins, M H ^f   Raskob, G E ^g  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^e SANOFI   (France)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Anticoagulants; Clinical trial; Idrabiotaparinux; Pulmonary embolism; Venous thrombosis

Indexed keywords

IDRABIOTAPARINUX; WARFARIN; ANTICOAGULANT AGENT; BIOTIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; OLIGOSACCHARIDE; VITAMIN K GROUP;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CONTROLLED STUDY; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TREATMENT DURATION; VEIN THROMBOSIS; ADULT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG ADMINISTRATION; EARLY TERMINATION OF CLINICAL TRIAL; ELECTROCARDIOGRAPHY; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PREDICTIVE VALUE; RISK FACTOR; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOTIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EARLY TERMINATION OF CLINICAL TRIALS; ELECTROCARDIOGRAPHY; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OLIGOSACCHARIDES; PREDICTIVE VALUE OF TESTS; RISK FACTORS; STROKE; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME; VITAMIN K; WARFARIN;

EID: 84902107567     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12546     Document Type: Article

References (9)

1. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
2. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 429S-56S.
3. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
4. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Moia M, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Siragusa S, Manotti C. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost 2012; 10: 1979-87.
5. The AMADEUS Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. The Lancet 2008; 371: 315-21.
6. Paty I, Trellu M, Destors JM, Cortze P, Boelle E, Sanderink G. Reversibility of the anti-Xa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010; 8: 722-9.
7. The Equinox investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost 2011; 9: 92-9.
8. Büller HR, Gallus AS, Pillion G, Prins MH, Raskob GE, on behalf of the CASSIOPEA Investigators. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. The Lancet 2012; 379: 123-9.
9. Fleming TR. Evaluation of active control trials in AIDS. J Acquir Immune Defic Syndr 1990; 3: S82-7.